Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
Guidelines Oriented Approach to Lipid lowering Quality Enhancement Research Initiative (GOAL QuERI) International	Canadian Heart Research Centre	Ongoing	any SFDA registered anti-hyperlipidemic product	4	CHRC2019	King Fahd Armed Forces Hospital (Jeddah), King Fahd Military Medical Complex (Dhahran), King Abdullah Medical Complex (Jeddah), King Fahad Hospital (Jeddah), King Fahad Genaral Hospital (Medina), King Khaled General Hospital (Hafar Al Batin), Royal Commission Hospital Jubail
Vortioxetine effectiveness overview for the treated MDE patients in Saudi Arabia	Lundbeck	Ongoing	BRINTELLIX 20 mg film-coated tablet/ BRINTELLIX 10 mg film-coated tablet	4	18620N	King Abdulaziz University Hospital (Jeddah), Saudi German Hospital (Jeddah), Dr. Erfan & Bagedo General Hospital (Jeddah), University Medical Center (Riyadh), Psych care Center (Riyadh), Dr. Sulaiman Al-Habib Medical Group Olaya (Riyadh), Al Moosa Specialized Hospital (al ahsa), King Fahad Medical City (Riyadh), Almana Hospital (Dammam), King Abdullah Medical Complex (Jeddah), Jeddah psychiatric hospital, Elite Medical Complex (Makkah)
A multicentre non-interventional study to assess the real-world effectiveness of Ocrelizumab in patients with relapsing or primary progressive multiple sclerosis – The MuSicalE STUDY	Roche	Ongoing	Ocrelizumab (Ocrevus)	4	MN39889	King Abdulaziz Medical City NG (Riyadh)
"Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)"	KAIMRC	Ongoing	• Ceftriaxone • Piperacillin Tazobactam • Azithromycin • Interferon β1-a • Hydrocortisone sodium suc.• Hydroxychloroquine • OSELTAMIVIR • Lopinavir-Ritonavir	3	CT20/001/R	King Abdulaziz Medical City NG (Riyadh)
A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19	KAIMRC	Ongoing	• Favipiravir• HYDROXYCHLOROQUINE SULPHATE	3	RC20/174/R	King Abdulaziz Medical City NG (Riyadh)
A Trial of Favipiravir in Adults with Mild Coronavirus Disease Covid-19	KAIMRC	Ongoing	Favipiravir	3	RC20/220/R	King Abdulaziz Medical City NG (Riyadh)
A National Collaborative Multicenter Phase II Study for Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19	GDRS (MOH)	Ongoing	Convalescent Plasma	2	20-COVID-19-01M	King Fahad Specialist Hospital (Dammam), International Medical Center (Jeddah), King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah), King Abdulaziz Hospital NG (Al Ahsa), Prince Mohammad bin Abdulaziz Hospital NG (Medina), Qatif Central Hospital, Dammam Medical Complex, King Fahad Medical City (Riyadh), King Saud Medical City (Riyadh), King Abdullah Medical City (Makkah), Al-Noor Specialist Hospital (Makkah), King Abdullah Medical Complex (Jeddah), Ohud hospital (Medina), King Fahad Genaral Hospital (Medina), Aseer Central Hospital (Abha)
An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care	GDRS (MOH)	Ongoing	• Hydroxychloroquine sulphate• CHLOROQUINE PHOSPHATE• Lopinavir/Ritonavir • Remdesivir• Interferon beta-1b	3	version 8	Qatif Central Hospital, Dammam Medical Complex, Ohud hospital (Medina), Al-Noor Specialist Hospital (Makkah), Prince Mohammad bin Abdulaziz hospital (Riyadh)
A phase II, multicenter, open label study of treatment escalation to ACVD (Adriamycin, Cyclophosphamide, Vinblastine and Dacarbazine) and Brentuximab-Vedotin in advanced-stage Hodgkin Lymphoma patients with a positive interim PET scan after 2 ABVD cycles (OPTIMIST study)	KAIMRC	Ongoing	• DOXORUBICIN HYDROCHLORIDE• CYCLOPHOSPHAMIDE• VINBLASTINE SULPHATE • DACARBAZINE• BRENTUXIMAB VEDOTIN	2	RC16/150	King Abdulaziz Medical City NG (Riyadh)
Phase 3, open label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-Padua) in adult male participants with moderately severe to severe hemophilia B (FIX:C<2%) (BeneGene-2)	Pfizer	Ongoing	PF-06838435	3	C0371002	King Faisal Specialist Hospital and Research Center (Riyadh)